Investigational drug · Phase 2
T3011
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
11
Any phase or sponsor naming "T3011"
First trial start
2020
Sep 17, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "T3011", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Nonmuscle-invasive Bladder Cancer
- Solid Tumor
- Melanoma
- HNSCC
- Sarcoma
- Squamous Cell Carcinoma
- NSCLC
- Advanced Melanoma
Approved drugs for the same conditions: Non-small cell lung cancer · Melanoma · Bladder and urothelial cancer · Sarcoma · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "T3011" as an intervention, largest first.
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknown
ImmVira Pharma Co. LtdIndustry
NCT05602792 · 233 participants (planned) · Start Apr 21, 2020 · Primary completion Jul 2023
Drug: T3011; T3011 and 5 more · For: Advanced Solid Tumor; Sarcoma; HNSCC and 4 more
Sites: Hefei, China; Guanzhou, China; Zhengzhou, China · 19 sites in all
ImmVira Pharma Co. LtdIndustry
NCT06971614 · 160 participants (planned) · Start Jun 9, 2025 · Primary completion Dec 31, 2028
Drug: T3011 · For: Nonmuscle-invasive Bladder Cancer
Sites: Queen Creek, Arizona; Los Angeles, California; Orlando, Florida · 9 sites in all
- A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.Status unknown
ImmVira Pharma Co. LtdIndustry
NCT05598268 · 74 participants (planned) · Start Mar 1, 2022 · Primary completion Jun 2024
Drug: T3011 · For: Advanced Solid Tumor; Lung Cancer; Liver Cancer and 2 more
Sites: Bengbu, China; Guanzhou, China; Luoyang, China · 7 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT06214143 · 68 participants (planned) · Start Jan 11, 2024 · Primary completion Dec 31, 2026
Drug: T3011 high dose; T3011 middle dose and 1 more · For: Advanced Solid Tumors
Sites: Anyang, China; Bengbu, China; Changsha, China · 22 sites in all
- Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid TumorsStatus unknown
ImmVira Pharma Co. LtdIndustry
NCT04780217 · 42 participants (planned) · Start Aug 10, 2021 · Primary completion Mar 2025
Drug: T3011 · For: Solid Tumor; Hepatocellular Carcinoma; Colorectal Cancer and 3 more
Sites: Phoenix, Arizona; Plantation, Florida; Greenville, South Carolina · 6 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT06214156 · 42 participants (planned) · Start Jan 26, 2024 · Primary completion Sep 30, 2026
Drug: T3011 · For: Advanced Melanoma
Sites: Beijing, China; Bengbu, China; Changchun, China · 7 sites in all
ImmVira Pharma Co. LtdIndustry
NCT04370587 · 30 participants (planned) · Start Sep 17, 2020 · Primary completion Sep 22, 2026
Drug: T3011 · For: Solid Tumor; Melanoma; HNSCC and 3 more
Sites: Gilbert, Arizona; Boston, Massachusetts; Pittsburgh, Pennsylvania · 9 sites in all
Fudan UniversityAcademic, hospital or other
NCT06427291 · 20 participants (planned) · Start Sep 21, 2023 · Primary completion Dec 31, 2025
Drug: Herpes virus T3011 injection · For: Bladder Cancer
Sites: Shanghai, China
- A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal CancerStatus unknown
West China HospitalAcademic, hospital or other
NCT06200363 · 15 participants (planned) · Start Sep 21, 2023 · Primary completion Nov 2024
Drug: T3011; Regorafenib · For: Advanced Colorectal Cancer
Sites: Chengdu, China
West China HospitalAcademic, hospital or other
NCT06200376 · 10 participants (planned) · Start Sep 28, 2023 · Primary completion Dec 2024
Drug: T3011 · For: Malignant Ascites
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.
Ji D, Fu W, Liu Y, et al. · BMC Med 2026
- Advances in the clinical development of oncolytic viruses.
Li K, Zhao Y, Hu X, et al. · Am J Transl Res 2022
- Determination of acrylamide in foods by pressurized fluid extraction and liquid chromatography-tandem mass spectrometry used for a survey of Spanish cereal-based foods.
Yusà V, Quintás G, Pardo O, et al. · Food Addit Contam 2006
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.